Global Medical Offers

28/12/2025

Jordan — Pharmaceutical Sector Snapshot (Latest Available Data)
Country at a Glance
• Capital: Amman
• Population: ~11.5 million
• Official Language: Arabic
• Strategic position as a regional pharmaceutical manufacturing and export hub in the Middle East
________________________________________
Pharmaceutical Trade Indicators
• Pharmaceutical Imports (HS 3004): ~USD 480 million
• Pharmaceutical Exports (HS 3004): ~USD 675 million
• Pharma Trade Balance: Positive surplus of ~USD 195 million
• Jordan remains one of the few net pharmaceutical exporters in the MENA region, driven by strong local manufacturers and regional demand.
________________________________________
Healthcare & Pharmaceutical Demand Drivers
• Current Health Expenditure per Capita: ~USD 430
• Health Expenditure as % of GDP: ~8.4%
• Out-of-Pocket Spending: ~28% of total health expenditure
• Government & Insurance Coverage: ~72%, supporting stable institutional demand for medicines.
________________________________________
Market Implications
• Strong export surplus highlights manufacturing maturity and regulatory credibility.
• Moderate out-of-pocket ratio reflects balanced public–private healthcare financing.
• Sustained healthcare spending supports long-term pharmaceutical market growth, tenders, and emergency supply opportunities.
________________________________________
Data Sources (as shown on poster)
• World Bank – World Development Indicators (WDI)
• World Bank – World Integrated Trade Solution (WITS)
• World Health Organization – Global Health Observatory (WHO GHO)
• Latest available reporting year per indicator

21/12/2025

🤝 We remain at your service worldwide through our regional offices & representatives:

🌍 GLOBAL MEDICAL OFFERS ( GMO GROUP )

🇺🇸 America & LATAM: wa.me/15642124801
🇬🇧 Europe & UK: wa.me/447400758141
🇮🇳 Asia & India: wa.me/919136931947
🇪🇬 Africa & Middle East: wa.me/201503526600
📧 Sales@gmo.group

✔️ For all inquiries on pharmaceuticals💊 & medicals 🩺, including urgent, shortage, or emerging supply, feel free to reach us anytime.

✨ Your trusted global healthcare partner

𝗦𝘂𝗯𝗺𝗶𝘁 𝘆𝗼𝘂𝗿 𝗶𝗻𝗾𝘂𝗶𝗿𝘆 𝗡𝗢𝗪 https://beta.gmo.group/quotation

Global Medical Offers for Medical & Pharmaceutical Market Services

19/12/2025

𝗦𝘂𝗯𝗺𝗶𝘁 𝘆𝗼𝘂𝗿 𝗶𝗻𝗾𝘂𝗶𝗿𝘆 𝗡𝗢𝗪 https://beta.gmo.group/quotation

🤝 We remain at your service worldwide through our regional offices & representatives:

🌍 GLOBAL MEDICAL OFFERS ( GMO GROUP )
🇺🇸 America & LATAM: wa.me/15642124801
🇬🇧 Europe & UK: wa.me/447400758141
🇮🇳 Asia & India: wa.me/919136931947
🇪🇬 Africa & Middle East: wa.me/201503526600
📧 Sales@gmo.group

✔️ For all inquiries on pharmaceuticals💊 & medicals 🩺, including urgent, shortage, or emerging supply, feel free to reach us anytime.

✨ Your trusted global healthcare partner

15/12/2025

𝗦𝘂𝗯𝗺𝗶𝘁 𝘆𝗼𝘂𝗿 𝗶𝗻𝗾𝘂𝗶𝗿𝘆 𝗡𝗢𝗪 https://beta.gmo.group/quotation

🤝 We remain at your service worldwide through our regional offices & representatives:

🌍 GLOBAL MEDICAL OFFERS ( GMO GROUP )

🇺🇸 America & LATAM: wa.me/15642124801
🇬🇧 Europe & UK: wa.me/447400758141
🇮🇳 Asia & India: wa.me/919136931947
🇪🇬 Africa & Middle East: wa.me/201503526600

📧 Sales@gmo.group

✔️ For all inquiries on pharmaceuticals 💊 & medicals 🩺, including urgent, shortage, or emerging supply, feel free to reach us anytime.

✨ Your trusted global healthcare partner

Global Medical Offers for Medical & Pharmaceutical Market Services

11/12/2025

for more details
sales@globalmedicaloffers.com
wa.me/919136931947

Global Medical Offers for Medical & Pharmaceutical Market Services

03/09/2025

📢 𝗧𝗵𝗲 𝗙𝘂𝘁𝘂𝗿𝗲 𝗼𝗳 𝗣𝗵𝗮𝗿𝗺𝗮 𝗪𝗵𝗼𝗹𝗲𝘀𝗮𝗹𝗲: 𝗞𝗲𝘆 𝗧𝗿𝗲𝗻𝗱𝘀 𝗥𝗲𝘀𝗵𝗮𝗽𝗶𝗻𝗴 𝟮𝟬𝟮𝟱

🌍 𝗜𝗻𝘁𝗿𝗼𝗱𝘂𝗰𝘁𝗶𝗼𝗻
The pharmaceutical wholesale industry is at the heart of global healthcare, ensuring patients and providers have access to safe, affordable, and innovative medicines. By 2025, wholesale distribution is projected to undergo transformative changes, shaped by technology, regulatory shifts, and global health demands.

At GLOBAL MEDICAL OFFERS (GMO GROUP), we are committed to staying ahead of these changes, delivering reliable and future-ready solutions to our partners worldwide.

📊 𝗠𝗮𝗿𝗸𝗲𝘁 𝗢𝘂𝘁𝗹𝗼𝗼𝗸
💰 $1.7 Trillion – The projected global pharmaceutical market size by 2025 (Statista).

📦 +6% CAGR – Expected annual growth rate of the pharma wholesale sector (Fortune Business Insights).

🌐 80% of hospitals and pharmacies rely on wholesalers for timely medicine supply (IQVIA).

🚀 Key Trends Reshaping 2025
1️⃣ Digitalization & Smart Supply Chains
Adoption of AI, blockchain, and IoT to track medicines in real-time.

Automation in warehouses reduces errors and increases efficiency.

Statistic: 70% of pharma distributors plan to invest in digital supply chain tools by 2025 (Deloitte).

2️⃣ Expansion of Biosimilars & Specialty Medicines
Biosimilars are driving affordability while maintaining quality.

Specialty medicines (oncology, biologics) account for 42% of market growth (IQVIA).

Wholesalers play a key role in ensuring equitable access.

3️⃣ Sustainability & Green Pharma
Focus on eco-friendly packaging and reducing carbon footprint.

By 2025, 65% of manufacturers will integrate sustainability targets (McKinsey).

Wholesalers adopting green logistics gain long-term competitive advantage.

4️⃣ Globalization & Emerging Markets
Strong demand growth from Asia, Africa, and the Middle East.

Emerging economies represent over 30% of global pharmaceutical demand by 2025 (WHO).

Reliable distribution networks are essential to meet this need.

🏥 Why It Matters
For hospitals, pharmacies, and healthcare providers, these trends mean:

Greater affordability & accessibility for patients.

Improved supply reliability and reduced shortages.

Stronger partnership opportunities with global wholesalers like GMO GROUP.

✅ Our Commitment at GLOBAL MEDICAL OFFERS
At GMO GROUP, we embrace innovation, compliance, and sustainability to:

Deliver trusted medical & pharmaceutical products worldwide.

Support partners with efficient sourcing & logistics.

Build a healthier, more connected world.

📚 References
IQVIA, Global Use of Medicines Report, 2024

Statista, Global Pharmaceutical Market Outlook 2025

Deloitte Insights, The Future of Supply Chain in Pharmaceuticals

McKinsey & Co., Sustainability in Pharma, 2025

Fortune Business Insights, Pharmaceutical Logistics Market Analysis 2025

29/08/2025

🌍 𝐅𝐃𝐀 𝐀𝐩𝐩𝐫𝐨𝐯𝐚𝐥 𝐨𝐟 𝐁𝐫𝐞𝐧𝐬𝐨𝐜𝐚𝐭𝐢𝐛 (𝐁𝐫𝐢𝐧𝐬𝐮𝐩𝐫𝐢) – 𝐀 𝐁𝐫𝐞𝐚𝐤𝐭𝐡𝐫𝐨𝐮𝐠𝐡 𝐢𝐧 𝐑𝐞𝐬𝐩𝐢𝐫𝐚𝐭𝐨𝐫𝐲 𝐌𝐞𝐝𝐢𝐜𝐢𝐧𝐞

📅 𝐈𝐧𝐭𝐫𝐨𝐝𝐮𝐜𝐭𝐢𝐨𝐧

On August 12, 2025, the U.S. Food and Drug Administration (FDA) granted approval to Brensocatib (Brinsupri), marking the first and only therapy ever approved for Non-Cystic Fibrosis Bronchiectasis (NCFBE).

This milestone represents a paradigm shift in respiratory medicine, providing a treatment option for a chronic and debilitating condition that until now had no FDA-approved pharmacological therapies.

Developed by Insmed Incorporated, a global leader in rare and serious diseases, Brensocatib is a novel, once-daily oral therapy that targets the underlying neutrophil-driven airway inflammation, addressing the root cause rather than just managing symptoms.

🏢 𝗔𝗯𝗼𝘂𝘁 𝘁𝗵𝗲 𝗠𝗮𝗻𝘂𝗳𝗮𝗰𝘁𝘂𝗿𝗲𝗿 – Insmed Incorporated

📍 Headquarters: Bridgewater, New Jersey, USA

🌐 Global Footprint: Operations across the U.S., Europe, and Japan

🔬 Therapeutic Focus: Rare diseases, pulmonology, and immunology with high unmet needs

📈 Pipeline Strategy:

Brensocatib under investigation for:

Chronic rhinosinusitis without nasal polyps (CRSsNP)

Hidradenitis suppurativa (HS)

Potential indications in COPD and asthma

Strong commitment to advancing first-in-class and platform therapies

🫁 𝐔𝐧𝐝𝐞𝐫𝐬𝐭𝐚𝐧𝐝𝐢𝐧𝐠 𝐍𝐨𝐧-𝐂𝐲𝐬𝐭𝐢𝐜 𝐅𝐢𝐛𝐫𝐨𝐬𝐢𝐬 𝐁𝐫𝐨𝐧𝐜𝐡𝐢𝐞𝐜𝐭𝐚𝐬𝐢𝐬 (𝐍𝐂𝐅𝐁𝐄)

🧾 Definition: A chronic, progressive lung disease characterized by irreversible dilation of the bronchi, recurrent bacterial infections, mucus buildup, and destructive inflammation.

⚠️ Unmet Need: Until Brensocatib, patients relied only on antibiotics, airway clearance devices, and symptomatic care with no disease-modifying therapies available.

📊 Burden: Affects hundreds of thousands globally, often leading to frequent hospitalizations, impaired quality of life, and high healthcare costs.

💊 𝗧𝗵𝗲 𝗣𝗿𝗼𝗱𝘂𝗰𝘁 – 𝗕𝗿𝗲𝗻𝘀𝗼𝗰𝗮𝘁𝗶𝗯 (𝗕𝗿𝗶𝗻𝘀𝘂𝗽𝗿𝗶)

𝗗𝗿𝘂𝗴 𝗖𝗹𝗮𝘀𝘀: Dipeptidyl peptidase-1 (DPP1) inhibitor

𝐅𝐨𝐫𝐦𝐮𝐥𝐚𝐭𝐢𝐨𝐧: Oral tablets (10 mg and 25 mg)

𝐌𝐞𝐜𝐡𝐚𝐧𝐢𝐬𝐦 𝐨𝐟 𝐀𝐜𝐭𝐢𝐨𝐧: Inhibits DPP1 enzyme activity, thereby preventing activation of neutrophil serine proteases – reducing destructive airway inflammation at its source.

🔬 𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗧𝗿𝗶𝗮𝗹 𝗘𝘃𝗶𝗱𝗲𝗻𝗰𝗲

Phase 3 – ASPEN Trial (NCT04594369)

👥 𝐌𝐞𝐜𝐡𝐚𝐧𝐢𝐬𝐦 𝐨𝐟 𝐀𝐜𝐭𝐢𝐨𝐧: ~1,680 adults and 41 adolescents with NCFBE

✅ Findings:

Significant reduction in annualized exacerbation rates

Delayed time to first exacerbation

Safety Profile: Generally favorable; most common adverse events were mild skin changes, upper respiratory infections, and headache.

Phase 2 – WILLOW Trial

Demonstrated long-term efficacy and tolerability

Provided pivotal data supporting Phase 3 advancement

💹 𝗠𝗮𝗿𝗸𝗲𝘁 𝗢𝘂𝘁𝗹𝗼𝗼𝗸 & 𝗦𝘁𝗿𝗮𝘁𝗲𝗴𝗶𝗰 𝗜𝗺𝗽𝗮𝗰𝘁

💰 Annual Therapy Cost (U.S.): Approx. $88,000 per patient

📈 Revenue Potential: Expected to achieve blockbuster status due to high unmet need

🏦 Investor Support: In mid-2025, Insmed raised $750 million to fund Brensocatib commercialization and expand its clinical pipeline

🌍 Global Expansion: Regulatory filings in Europe and Japan expected in 2026

🌐 𝐆𝐥𝐨𝐛𝐚𝐥 & 𝐒𝐭𝐫𝐚𝐭𝐞𝐠𝐢𝐜 𝐈𝐦𝐩𝐥𝐢𝐜𝐚𝐭𝐢𝐨𝐧𝐬

🔑 First-in-Class: Brensocatib is the only approved therapy for NCFBE worldwide

🧩 Platform Potential: Active trials in multiple neutrophil-driven diseases suggest broad therapeutic applications

🏆 FDA Milestone: Reinforces the agency’s commitment to supporting innovative therapies for high unmet medical needs

🚀 Insmed Leadership: Solidifies Insmed’s reputation as a pioneer in respiratory innovation and sets the stage for cross-indication growth

📚 𝗥𝗲𝗳𝗲𝗿𝗲𝗻𝗰𝗲𝘀

Medscape: FDA Approves Brensocatib

Reuters: FDA Approves Insmed’s Drug for Chronic Lung Disease

Drugs.com: Brinsupri Approval Details

Pulmonology Advisor: Brensocatib in Bronchiectasis

Investor.Insmed.com: ASPEN Study Results

Barron’s: Insmed Stock Rises After Positive ASPEN Results

Investors.com: Insmed’s “Skeleton Key” Drug

27/08/2025

𝑼𝒏𝒍𝒐𝒄𝒌 𝒕𝒉𝒆 𝑭𝒖𝒕𝒖𝒓𝒆 𝒐𝒇 𝑷𝒉𝒂𝒓𝒎𝒂 𝒊𝒏 𝑴𝑬𝑵𝑨

𝗣𝗵𝗮𝗿𝗺𝗮𝗰𝗼𝗻𝗲𝘅 𝗘𝗴𝘆𝗽𝘁 𝟮𝟬𝟮𝟱—the premier pharmaceutical exhibition across the MENA region—returns to the Egypt International Exhibition Center (EIEC) in Cairo from September 1–3, 2025. Spanning three action-packed days, the event brings together over 350 exhibitors, more than 13,500 industry professionals, and representation from 40+ countries, all converging to explore innovation, collaboration, and growth in the pharmaceutical and medical.
𝗪𝗵𝘆 #𝗣𝗵𝗮𝗿𝗺𝗮𝗰𝗼𝗻𝗲𝘅 𝗖𝗮𝗻𝗻𝗼𝘁 𝗕𝗲 𝗠𝗶𝘀𝘀𝗲𝗱
Dynamic Exhibitor Landscape: With 350+ international participants across nine specialized sectors—APIs, biopharmaceuticals, lab equipment, packaging, cleanrooms, and more—it’s a powerhouse of product discovery and supply chain
𝗚𝗹𝗼𝗯𝗮𝗹 𝗡𝗲𝘁𝘄𝗼𝗿𝗸 𝗔𝗰𝗰𝗲𝘀𝘀: Join over 13,500 attendees including manufacturers, regulators, R&D experts, distributors, and regulators from around the world.
𝗞𝗻𝗼𝘄𝗹𝗲𝗱𝗴𝗲 𝗛𝘂𝗯: Attend 70+ conference sessions covering cleanroom technologies, regulatory trends, digital transformation, sustainability, and more.
𝗣𝗿𝗼𝘃𝗲𝗻 𝗚𝗿𝗼𝘄𝘁𝗵 & 𝗜𝗺𝗽𝗮𝗰𝘁: #𝗣𝗵𝗮𝗿𝗺𝗮𝗰𝗼𝗻𝗲𝘅 has demonstrated remarkable momentum—achieving a 117% increase in exhibition volume and a 150% surge in attendance over recent years, solidifying its status as Africa’s leading pharma
𝗘𝗺𝗲𝗿𝗴𝗶𝗻𝗴 𝗠𝗮𝗿𝗸𝗲𝘁 𝗠𝗼𝗺𝗲𝗻𝘁𝘂𝗺:
North Africa’s pharma market is projected to grow from US $12.98 Bn in 2018 to US $22.23 Bn by 2025,
Middle East & Africa : Egypt, as the largest MENA producer, already manufactures ~90% of its consumed drugs, with its pharma market growing from US $3.1 Bn in 2018 to US $5.2 Bn by 2025.

𝗚𝗹𝗼𝗯𝗮𝗹 𝗠𝗲𝗱𝗶𝗰𝗮𝗹 𝗢𝗳𝗳𝗲𝗿𝘀 (𝗚𝗠𝗢 𝗚𝗥𝗢𝗨𝗣): Your Growth Catalyst
At Global Medical Offers, we provide tailored solutions for international healthcare and pharmaceutical firms looking to establish or expand across the Middle East & Africa. Our deep regional expertise and strategic capabilities include:

𝗠𝗮𝗿𝗸𝗲𝘁 𝗘𝗻𝘁𝗿𝘆 𝗘𝘅𝗰𝗲𝗹𝗹𝗲𝗻𝗰𝗲: Local regulatory know-how, distribution setup, and licensing strategy.
Strategic Expansion: Partner sourcing, sales channel development, and actionable expansion roadmaps.
𝗜𝗻𝘁𝗲𝗴𝗿𝗮𝘁𝗲𝗱 𝗦𝘂𝗽𝗽𝗼𝗿𝘁: From procurement and supply chain to product lifecycle management and local representation.

𝗖𝗼𝗻𝗻𝗲𝗰𝘁 𝘄𝗶𝘁𝗵 𝗚𝗠𝗢 𝗮𝘁 𝗣𝗵𝗮𝗿𝗺𝗮𝗰𝗼𝗻𝗲𝘅 𝗘𝗴𝘆𝗽𝘁 𝟮𝟬𝟮𝟱
𝗕𝗲𝗻𝗲𝗳𝗶𝘁 𝗪𝗵𝗮𝘁 𝗬𝗼𝘂 𝗚𝗮𝗶𝗻

𝗢𝗻𝘀𝗶𝘁𝗲 𝗔𝗰𝗰𝗲𝘀𝘀 Meet our team face-to-face to co-create bespoke strategies for pe*******on into MENA & Africa markets.

𝗥𝗲𝗴𝗶𝗼𝗻𝗮𝗹 𝗜𝗻𝘀𝗶𝗴𝗵𝘁 Unlock market data, regulatory trends, and emerging opportunities across economies like Egypt, KSA, UAE, Nigeria, Kenya, and beyond.

𝗣𝗮𝗿𝘁𝗻𝗲𝗿𝘀𝗵𝗶𝗽 𝗦𝘆𝗻𝗲𝗿𝗴𝗶𝗲𝘀 Foster impactful collaborations with a trusted regional player that aligns with your business goals.

𝗬𝗼𝘂𝗿 𝗡𝗲𝘅𝘁 𝗠𝗼𝘃𝗲 𝗦𝘁𝗮𝗿𝘁𝘀 𝗛𝗲𝗿𝗲
𝑀𝑒𝑒𝑡 𝐺𝑙𝑜𝑏𝑎𝑙 𝑀𝑒𝑑𝑖𝑐𝑎𝑙 𝑂𝑓𝑓𝑒𝑟𝑠 𝑎𝑡 𝑃ℎ𝑎𝑟𝑚𝑎𝑐𝑜𝑛𝑒𝑥 𝐸𝑔𝑦𝑝𝑡, 𝑆𝑒𝑝𝑡𝑒𝑚𝑏𝑒𝑟 1–3, 2025, 𝑎𝑡 𝑡ℎ𝑒 𝐸𝑔𝑦𝑝𝑡 𝐼𝑛𝑡𝑒𝑟𝑛𝑎𝑡𝑖𝑜𝑛𝑎𝑙 𝐸𝑥ℎ𝑖𝑏𝑖𝑡𝑖𝑜𝑛 𝐶𝑒𝑛𝑡𝑒𝑟, 𝐶𝑎𝑖𝑟𝑜. 𝑇ℎ𝑖𝑠 𝑖𝑠 𝑚𝑜𝑟𝑒 𝑡ℎ𝑎𝑛 𝑎𝑛 𝑒𝑥ℎ𝑖𝑏𝑖𝑡𝑖𝑜𝑛—𝑖𝑡’𝑠 𝑡ℎ𝑒 𝑙𝑎𝑢𝑛𝑐ℎ𝑝𝑎𝑑 𝑓𝑜𝑟 𝑦𝑜𝑢𝑟 𝑀𝐸𝑁𝐴 & 𝐴𝑓𝑟𝑖𝑐𝑎 𝑒𝑥𝑝𝑎𝑛𝑠𝑖𝑜𝑛.

𝑇𝑜𝑔𝑒𝑡ℎ𝑒𝑟, 𝑤𝑒 𝑡𝑢𝑟𝑛 𝑝𝑜𝑡𝑒𝑛𝑡𝑖𝑎𝑙 𝑖𝑛𝑡𝑜 𝑝𝑒𝑟𝑓𝑜𝑟𝑚𝑎𝑛𝑐𝑒.

𝘗𝘭𝘦𝘢𝘴𝘦 𝘧𝘦𝘦𝘭 𝘧𝘳𝘦𝘦 𝘵𝘰 𝘤𝘰𝘯𝘵𝘢𝘤𝘵 𝘶𝘴 📧 | Sales@gmo.group | 𝗪𝗵𝗮𝘁𝘀𝗔𝗽𝗽 |+1 73 72 73 32 75

27/08/2025

🌍 𝘽𝙞𝙤𝙨𝙞𝙢𝙞𝙡𝙖𝙧𝙨: 𝙏𝙝𝙚 𝙉𝙚𝙭𝙩 𝙁𝙧𝙤𝙣𝙩𝙞𝙚𝙧 𝙞𝙣 𝘽𝙞𝙤𝙥𝙝𝙖𝙧𝙢𝙖𝙘𝙚𝙪𝙩𝙞𝙘𝙖𝙡𝙨

Biologics have revolutionized treatment in oncology, autoimmune diseases, and chronic care—but their high costs remain a barrier for healthcare systems and patients worldwide. Enter biosimilars: safe, effective, and more affordable alternatives that are transforming global access to advanced therapies.

📈 𝗖𝘂𝗿𝗿𝗲𝗻𝘁 𝗠𝗮𝗿𝗸𝗲𝘁 𝗧𝗿𝗲𝗻𝗱𝘀
The global biosimilars market was valued at ~USD 25–33 billion in 2023–24 and is projected to grow to USD 72–118 billion by 2033, depending on methodology and therapeutic segment (MarketsandMarkets, Dimension Research).
Europe leads adoption, with over 90 biosimilars approved by the EMA, supported by substitution policies and payer incentives.
The U.S. is catching up: the FDA has now approved 45+ biosimilars, including “interchangeable” ones that can be substituted at the pharmacy.
Emerging markets (India, China, LATAM) are rapidly expanding, driven by cost savings and local manufacturing capabilities.

💊 𝗧𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰 𝗔𝗿𝗲𝗮𝘀 𝗗𝗿𝗶𝘃𝗶𝗻𝗴 𝗚𝗿𝗼𝘄𝘁𝗵
Oncology – Biosimilars of trastuzumab (Herceptin®), rituximab (Rituxan®), and bevacizumab (Avastin®) dominate due to high cancer prevalence and cost pressures.
Autoimmune Disorders – Biosimilars of adalimumab (Humira®), infliximab (Remicade®), and etanercept (Enbrel®) are widely used in rheumatoid arthritis, psoriasis, and IBD.
Diabetes – Insulin glargine (Lantus®) biosimilars are enabling wider access to affordable diabetes management.
Future pipeline – GLP-1 agonist biosimilars (e.g., semaglutide, for diabetes and obesity) represent a multi-billion-dollar opportunity as patents expire by 2026–2031.

🏭 𝗞𝗲𝘆 𝗣𝗹𝗮𝘆𝗲𝗿𝘀 𝗶𝗻 𝘁𝗵𝗲 𝗕𝗶𝗼𝘀𝗶𝗺𝗶𝗹𝗮𝗿 𝗟𝗮𝗻𝗱𝘀𝗰𝗮𝗽𝗲
Sandoz (Novartis spin-off) – global leader with biosimilars like Hyrimoz® (adalimumab) and Zarxio® (filgrastim).
Samsung Bioepis (Samsung Biologics & Biogen JV) – strong oncology and autoimmune portfolio.
Amgen – launched Amjevita® (adalimumab biosimilar) and several oncology biosimilars.
Pfizer – products like Retacrit® (epoetin alfa) and oncology biosimilars.
Biocon Biologics (India) – partnered with Viatris; strong presence in insulin and oncology biosimilars.
Celltrion (South Korea) – Remsima® (infliximab biosimilar), Truxima® (rituximab).

🔮 𝗙𝘂𝘁𝘂𝗿𝗲 𝗢𝘂𝘁𝗹𝗼𝗼𝗸
Cost savings: Biosimilars are expected to save >$180 billion globally over the next decade, improving affordability for patients and reducing payer burden.
Regulatory harmonization: EMA, FDA, and WHO are working toward global standards to accelerate approvals.
Manufacturing innovation: Single-use bioreactors, AI-driven bioprocessing, and global partnerships are reducing costs and improving scalability.
Therapeutic expansion: Oncology, autoimmune, insulin, and upcoming GLP-1 biosimilars will shape the next growth wave.

✅ 𝗖𝗼𝗻𝗰𝗹𝘂𝘀𝗶𝗼𝗻
Biosimilars are no longer an alternative—they are a strategic pillar of modern healthcare. With strong growth in oncology, autoimmune diseases, and metabolic disorders, and with major pharma and biotech players investing heavily, biosimilars are set to reshape patient access, payer economics, and pharmaceutical competition worldwide.

🔖 𝙍𝙚𝙛𝙚𝙧𝙚𝙣𝙘𝙚𝙨
MarketsandMarkets: Biosimilars Market Report 2024–2035
Dimension Market Research (2024): Global Biosimilars Forecast to 2033
European Medicines Agency (EMA) – Biosimilars approvals list
FDA – Biosimilars approved in the U.S. (Drugs@FDA database)
Reuters, FT, WSJ, VerywellHealth (2024) – industry insights on Humira and CVS biosimilar adoption

27/08/2025

𝑻𝒉𝒆 𝑭𝒊𝒓𝒔𝒕 𝒂𝒏𝒅 𝒐𝒏𝒍𝒚 𝑭𝑫𝑨-𝒂𝒑𝒑𝒓𝒐𝒗𝒆𝒅 𝒂𝒄𝒆𝒄𝒍𝒊𝒅𝒊𝒏𝒆-𝒃𝒂𝒔𝒆𝒅 𝒆𝒚𝒆 𝒅𝒓𝒐𝒑
VIZZ™ Eye Drops
𝙊𝙫𝙚𝙧𝙫𝙞𝙚𝙬
VIZZ (aceclidine ophthalmic solution) 1.44% is the first and only FDA-approved aceclidine-based eye drop for treating presbyopia in adults, offering a groundbreaking pharmacological solution in vision care.

𝙆𝙚𝙮 𝙁𝙚𝙖𝙩𝙪𝙧𝙚𝙨 & 𝙈𝙚𝙘𝙝𝙖𝙣𝙞𝙨𝙢 𝙤𝙛 𝘼𝙘𝙩𝙞𝙤𝙣
𝗔𝗰𝘁𝗶𝘃𝗲 𝗜𝗻𝗴𝗿𝗲𝗱𝗶𝗲𝗻𝘁: Aceclidine, a pupil-selective miotic that contracts the iris sphincter muscle—creating a “pinhole effect” (sub-2 mm pupil) to enhance depth of focus and improve near vision, while minimally affecting the eye’s focusing (ciliary) muscles.
𝗥𝗮𝗽𝗶𝗱 𝗢𝗻𝘀𝗲𝘁 & 𝗗𝘂𝗿𝗮𝘁𝗶𝗼𝗻: Vision improvement begins within roughly 30 minutes and lasts up to 10 hours.
𝗙𝗼𝗿𝗺𝘂𝗹𝗮𝘁𝗶𝗼𝗻: Preservative-free, provided in single-use vials, and administered once daily.

𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗗𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁 & 𝗔𝗽𝗽𝗿𝗼𝘃𝗮𝗹
𝗙𝗗𝗔 𝗔𝗽𝗽𝗿𝗼𝘃𝗮𝗹: Granted in July 2025, with commercial availability anticipated mid–Q4 2025; samples expected from October 2025
𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗧𝗿𝗶𝗮𝗹𝘀: Based on rigorous Phase 3 clinical trials—CLARITY-1, CLARITY-2 (466 subjects over 42 days), and CLARITY-3 (217 subjects for 6 months)—demonstrating both efficacy and safety.
𝗧𝗼𝗹𝗲𝗿𝗮𝗯𝗶𝗹𝗶𝘁𝘆: Well-tolerated overall, no serious adverse events observed across over 30,000 treatment days Eyes.

𝙎𝒂𝙛𝒆𝙩𝒚 & 𝑨𝙙𝒎𝙞𝒏𝙞𝒔𝙩𝒓𝙖𝒕𝙞𝒐𝙣 𝙂𝒖𝙞𝒅𝙚𝒍𝙞𝒏𝙚𝒔
Usage Directions (per FDA Prescribing Information):
Remove contact lenses before use; reinsert after 10 minutes.
Administer one drop in each eye, wait 2 minutes, then apply a second drop in each eye—once daily.
If using other topical ophthalmic medications, space them at least 5 minutes apart.

𝗜𝗺𝗽𝗼𝗿𝘁𝗮𝗻𝘁 𝗪𝗮𝗿𝗻𝗶𝗻𝗴𝘀 & 𝗣𝗿𝗲𝗰𝗮𝘂𝘁𝗶𝗼𝗻𝘀:
Blurred or dim vision may occur; advise against driving or operating machinery until vision clears.
Retinal tear/detachment risk (rare); pre-treatment retinal examination recommended; caution patients to report flashes, floaters, or vision loss.
Hypersensitivity: Contraindicated in patients allergic to aceclidine or any component of VIZZ.
Avoid contact between vial tip and eye or surfaces to prevent injury/contamination; discard the vial immediately after use.

𝐑𝐞𝐩𝐨𝐫𝐭𝐞𝐝 𝐒𝐢𝐝𝐞 𝐄𝐟𝐟𝐞𝐜𝐭𝐬 (𝐟𝐫𝐨𝐦 𝐜𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐭𝐫𝐢𝐚𝐥𝐬):
Instillation site irritation (20%)
Dim vision (16%)
Headache (13%)
Additional effects (>5%): conjunctival hyperemia (8%), ocular hyperemia (7%)—all generally mild, transient, and self-resolving FDA Access

𝐂𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐒𝐢𝐠𝐧𝐢𝐟𝐢𝐜𝐚𝐧𝐜𝐞
𝗧𝗿𝗮𝗻𝘀𝗳𝗼𝗿𝗺𝗮𝘁𝗶𝘃𝗲 𝗧𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁: VIZZ marks a new era—replacing reading glasses with a convenient, pharmacological alternative that offers up to 10 hours of near vision clarity.
𝗖𝗮𝘁𝗲𝗴𝗼𝗿𝘆 𝗟𝗲𝗮𝗱𝗲𝗿: Unlike traditional myotics like Vuity, VIZZ avoids stimulating the ciliary muscle, thus preventing distance vision blurring or “zoomed-in” effects.
𝗙𝗶𝗿𝘀𝘁 𝗣𝗵𝗮𝗿𝗺𝗮𝗰𝗼𝗹𝗼𝗴𝗶𝗰𝗮𝗹 𝗔𝗽𝗽𝗿𝗼𝗮𝗰𝗵: It’s the first pharmacological treatment for presbyopia approved by the FDA, signaling a shift in vision care toward non-invasive, patient-empowering solutions.

NOW YOU CAN CHECK OUR SERVICES & PRODCUTS - https://GLOBALMEDICALOFFERS.com

27/08/2025

𝘽𝙧𝙚𝙖𝙠𝙩𝙝𝙧𝙤𝙪𝙜𝙝 𝙞𝙣 𝙃𝙮𝙥𝙚𝙧𝙩𝙚𝙣𝙨𝙞𝙤𝙣 𝙏𝙧𝙚𝙖𝙩𝙢𝙚𝙣𝙩: 𝙁𝘿𝘼 𝘼𝙥𝙥𝙧𝙤𝙫𝙚𝙨 𝙁𝙞𝙧𝙨𝙩 𝙏𝙧𝙞𝙥𝙡𝙚-𝘾𝙤𝙢𝙗𝙞𝙣𝙖𝙩𝙞𝙤𝙣 𝙋𝙞𝙡𝙡

June 9, 2025 The U.S. Food and Drug Administration (FDA) has granted approval to Widaplik (formerly GMRx2), marking the first-ever single-pill triple-combination therapy for hypertension. This novel formulation combines telmisartan (ARB), amlodipine (CCB), and indapamide (diuretic), designed to simplify and enhance blood pressure (BP) management in adults—even as initial therapy by prescription. Pharmacy

𝐂𝐨𝐦𝐩𝐨𝐬𝐢𝐭𝐢𝐨𝐧 & 𝐃𝐨𝐬𝐚𝐠𝐞 𝐎𝐩𝐭𝐢𝐨𝐧𝐬
Widaplik is available in three dosage strengths allowing for tailored therapy:

10/1.25/0.625 mg (low dose)
20/2.5/1.25 mg (intermediate)
40/5/2.5 mg (standard)

Its triple-mechanism targets vascular resistance, calcium-channel effects, and fluid balance—offering a broad-spectrum approach to BP reduction.

𝐂𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐄𝐟𝐟𝐢𝐜𝐚𝐜𝐲: 𝐏𝐡𝐚𝐬𝐞 𝟑 𝐓𝐫𝐢𝐚𝐥𝐬
GMRx2_ACT (Active-Controlled Trial)
Compared Widaplik against dual combos: telmisartan+amlodipine, telmisartan+indapamide, amlodipine+indapamide.
At 12 weeks, mean home systolic BP (SBP) reduction was significantly greater for Widaplik—from baseline to ~126 mm Hg—versus all dual therapies (differences ranging from –2.5 to –5.4 mm Hg; P

14/05/2025

We are looking for a Wholsaler Phamaceuticals from Turkey 🇹🇷 are ready for shipping
📞 | Wa.me/201503526600
📞 | Wa.me/17372733275
📧 | Sales@gmo.group